Jennison Associates LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 8.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,020,278 shares of the company's stock after purchasing an additional 83,115 shares during the quarter. Jennison Associates LLC owned 1.13% of NewAmsterdam Pharma worth $16,937,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Banque Cantonale Vaudoise purchased a new position in NewAmsterdam Pharma during the second quarter worth $38,000. Rosalind Advisors Inc. acquired a new position in NewAmsterdam Pharma in the 2nd quarter valued at $194,000. Wolverine Asset Management LLC lifted its stake in shares of NewAmsterdam Pharma by 117.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company's stock worth $298,000 after purchasing an additional 8,394 shares during the period. Sei Investments Co. boosted its holdings in shares of NewAmsterdam Pharma by 49.1% during the second quarter. Sei Investments Co. now owns 24,561 shares of the company's stock worth $472,000 after purchasing an additional 8,087 shares during the last quarter. Finally, Lisanti Capital Growth LLC acquired a new position in NewAmsterdam Pharma in the third quarter valued at $700,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.
NewAmsterdam Pharma Stock Up 0.4 %
NASDAQ NAMS traded up $0.08 during trading hours on Friday, hitting $20.20. The company had a trading volume of 996,236 shares, compared to its average volume of 678,748. The firm's 50 day moving average is $19.07 and its 200 day moving average is $18.59. NewAmsterdam Pharma has a fifty-two week low of $8.90 and a fifty-two week high of $26.35.
Insider Transactions at NewAmsterdam Pharma
In related news, CAO Louise Frederika Kooij sold 45,000 shares of the firm's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock in a transaction on Friday, November 15th. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60. Following the sale, the insider now directly owns 11,812,033 shares in the company, valued at $295,537,065.66. This trade represents a 0.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 86,803 shares of company stock valued at $1,755,307 over the last quarter. Company insiders own 19.50% of the company's stock.
Analyst Ratings Changes
Several research analysts have recently weighed in on NAMS shares. Piper Sandler reiterated an "overweight" rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Royal Bank of Canada restated an "outperform" rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Needham & Company LLC reissued a "buy" rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $33.80.
Read Our Latest Analysis on NewAmsterdam Pharma
NewAmsterdam Pharma Profile
(
Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Further Reading
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.